Endeavor Biomedicines
Endeavor’s ENV-101 is a second-generation Hedgehog inhibitor with a highly favorable efficacy and side-effect profile compared to the molecules currently in the market. ENV-101 inhibits target pathway by ~90% at all tested doses.
Enquyst Technologies
Enquyst Technologies is developing the next-generation biopharmaceutical manufacturing platform which aims to redesign the downstream bioprocess equipment to bring unprecedented advantages in cost, time, footprint, and speed to market at commercial scale.
